What Researchers Did
Researchers retrospectively analyzed 98 patients with slow coronary flow, comparing those who received hyperbaric oxygen therapy plus conventional treatment (n=48) with a control group receiving conventional treatment alone (n=50) over 4 weeks.
What They Found
Before treatment, there were no significant differences in vascular endothelial function markers between the two groups (p > 0.05). After 4 weeks, the hyperbaric oxygen group showed significantly increased flow-mediated vasodilation (FMD) and plasma levels of nitric oxide (NO) and calcitonin gene-related peptide (CGRP) compared to the control group.
What This Means for Canadian Patients
Canadian patients experiencing slow coronary flow might potentially benefit from hyperbaric oxygen therapy as an add-on to conventional treatment. This could lead to improved vascular endothelial function, which is important for heart health, but more research is needed to confirm its routine use.
Canadian Relevance
This study was conducted in China and has no direct Canadian connection.
Study Limitations
As a retrospective study with a relatively small sample size of 98 patients, the findings may not be broadly generalizable.